High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.

Introduction The choice of therapy in patients withdrawing from natalizumab treatment is still an open question and neurologists need strategies to manage this group of patients. The aim of this study is to evaluate if alemtuzumab is able to control the disease when used in patient who have stopped natalizumab.